{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:45:25Z","timestamp":1789011925974,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.hoc.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T19:34:37Z","timestamp":1510947277000},"page":"23-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["The Role of Interleukin-6 in Castleman Disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Kazuyuki","family":"Yoshizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2017.09.003_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.4049\/jimmunol.128.3.1296","article-title":"Induction of proliferation and Igs-production in human B leukemic cells by anti-immunoglobulins and T\u00a0cell factors","volume":"128","author":"Yoshizaki","year":"1982","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2017.09.003_bib2","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.132.6.2948","article-title":"Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lympho-blastoid cell line","volume":"132","author":"Yoshizaki","year":"1984","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2017.09.003_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2017.09.003_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2443.2005.00900.x","article-title":"Essential role of STAT3 in cytokine-driven NF-\u03baB-mediated serum amyloid A gene expression","volume":"10","author":"Hagihara","year":"2005","journal-title":"Genes Cells"},{"key":"10.1016\/j.hoc.2017.09.003_bib5","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.4049\/jimmunol.180.5.3492","article-title":"Transcriptional Complex formation of c-Fos, STAT3, and hepatocyte NF-1\u03b1 is essential for cytokine-driven C-reactive protein gene expression","volume":"180","author":"Nishikawa","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"18","key":"10.1016\/j.hoc.2017.09.003_bib6","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (Tocilizumb) improves anemia of inflammation in multicentric Castleman\u2019s disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.003_bib7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receeptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.hoc.2017.09.003_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2017.09.003_bib9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.1985.3.9.1202","article-title":"A\u00a0systemic lymphoproliferative disorder with morphologic features of Castleman\u2019s disease: clinical findings and clinicopathologic correlations in 15 patients","volume":"3","author":"Frizzera","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2017.09.003_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin 6 (IL-6\/BSF-2) in Castleman\u2019s disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.09.003_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0192-0561(92)90173-I","article-title":"IL-6 receptor and mechanism of signal transduction","volume":"14","author":"Kishimoto","year":"1992","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.hoc.2017.09.003_bib12","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin-6-de-pendent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2017.09.003_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman\u2019s disease like symptoms emerged in IL-6 transgenic mice","volume":"20","author":"Katsume","year":"2002","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.003_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2492\/inflammregen.32.099","article-title":"Up-regulation of hepcidin by interleukin-6 contributes to anemia of inflammation in multicentric Castleman\u2019s disease (MCD)","volume":"32","author":"Song","year":"2012","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.hoc.2017.09.003_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.09.003_bib16","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman\u2019s disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.003_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3960\/jslrt.53.69","article-title":"Clinical features and treatment of multicentric Castleman\u2019s disease : a retrospective study of 21 Japanese patients at a single institute","volume":"53","author":"Kawabata","year":"2013","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.hoc.2017.09.003_bib18","unstructured":"Report of clinical study of tocilizumub therapy to multi centric Castleman\u2019s disease in Japan. Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Available at: http:\/\/www.pmda.go.jp\/drugs_reexam\/2016\/P20161005001\/450045000_21900AMX01337_A100_1.pdf. Accessed August 8, 2017."},{"key":"10.1016\/j.hoc.2017.09.003_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximub for multi centric Castleman\u2019s disease: a randomized, double-blind, placebo- controlled trial","volume":"15","author":"Van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2017.09.003_bib20","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.hoc.2017.09.003_bib21","series-title":"XIIIth International Symposium on Amyloidosis","first-page":"394","article-title":"Basic and clinical significance of interleukin 6 (IL-6) in AA amyloidosis","author":"Yoshizaki","year":"2013"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:05:15Z","timestamp":1760184315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817301430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0889858817301430"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Interleukin-6 in Castleman Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}